11 completed, 2 active not recruiting, 2 terminated, 1 unknown. 16 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 11, Active not recruiting 2, Terminated 2, Unknown 1 |
| Phase 1 | 2 | Active not recruiting 1, Completed 1 |
Follow Neoplasms, Fibroepithelial: new trials by email Literature Review of Neoplasms, Fibroepithelial trials Research Report on Neoplasms, Fibroepithelial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Analgesic Efficacy of Pulsed Radiofrequency in Non-cyclic Mastalgia pulsed radiofrequency of 2nd , 3rd and 4th thoracic dorsal root ganglia., Tamoxifen - Breast Fibroadenoma | Phase 2 | Completed | Mansoura University | 64 | 2018-08-15 | 2019-03-07 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer metformin hydrochloride, placebo, Chemotherapy - Brenner Tumor, Malignant Ascites | Phase 2 | Completed | University of Chicago | 111 | 2015-02-25 | 2026-03-27 |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Adavosertib, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 124 | 2014-07-21 | 2026-11-13 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer pegylated liposomal doxorubicin (PLD), VTX-2337, Placebo - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Completed | Celgene | 297 | 2012-10-31 | 2019-09-26 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Elesclomol Sodium, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | GOG Foundation | 58 | 2010-12-13 | 2021-10-20 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Bevacizumab, Carboplatin, Paclitaxel - Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 33 | 2010-04-14 | 2022-10-28 |
| Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin belinostat, carboplatin - Brenner Tumor, Fallopian Tube Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 29 | 2009-12-01 | 2019-07-23 |
| A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 2 | Completed | Gynecologic Oncology Group | 31 | 2009-07-01 | 2019-01-15 |
| Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy sargramostim, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis - Brenner Tumor, Fallopian Tube Cancer | Phase 2 | Completed | University of Washington | 21 | 2006-05-01 | 2017-08-28 |
| Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer carboplatin, paclitaxel, cytoreductive surgery - Fallopian Tube Cancer, Ovarian Cancer | Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 7 | 2005-10-01 | 2017-12-28 |
| Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer pegfilgrastim, carboplatin, docetaxel - Fallopian Tube Cancer, Ovarian Cancer | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 2004-06-01 | 2010-09-21 | |
| Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma paclitaxel, carboplatin, erlotinib - Brenner Tumor, Fallopian Tube Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 56 | 2003-04-01 | 2015-12-01 |
| Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases Imatinib mesylate - Life Threatening Diseases | Phase 2 | Completed | Novartis Pharmaceuticals | 185 | 2001-02-01 | 2016-11-18 |
| Combination Chemotherapy Plus IM-862 in Treating Patients With Resected Stage III Ovarian Cancer or Primary Peritoneal Cancer carboplatin, oglufanide disodium, paclitaxel - Ovarian Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Unknown | Cytran | 2001-01-01 | 2013-11-06 |
Brenner Tumor (15) · Fallopian Tube Neoplasms (13) · Ovarian Neoplasms (9) · Carcinoma, Ovarian Epithelial (8) · Adenocarcinoma (1) · Carcinoma, Adenoid Cystic (1) · Carcinoma, Ductal, Breast (1) · Carcinoma, Renal Cell (1) · Chondrosarcoma (1) · Chordoma (1) · Dermatofibrosarcoma (1) · Fibroadenoma (1) · Fibroma (1) · Hemangiopericytoma (1) · Hemangiosarcoma (1)
Neoplasms by Histologic Type (16) · Neoplasms, Connective Tissue (16) · Neoplasms, Connective and Soft Tissue (16) · Neoplasms, Fibrous Tissue (16) · Neoplasms, Glandular and Epithelial (16) · Adnexal Diseases (15) · Endocrine System Diseases (15) · Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Genital Diseases (15) · Genital Diseases, Female (15) · Genital Neoplasms, Female (15) · Gonadal Disorders (15) · Neoplasms (15)
Carboplatin (6) · Paclitaxel (6) · Taxes (5) · Bevacizumab (2) · Disulfides (2) · Erlotinib Hydrochloride (2) · Immunoglobulin G (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Cytoreduction Surgical Procedures (1) · Docetaxel (1) · Drug Therapy (1) · Gemcitabine (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Imatinib Mesylate (1)
National Cancer Institute (NCI) (3) · M.D. Anderson Cancer Center (2) · Celgene (1) · Cytran (1) · Fred Hutchinson Cancer Center (1) · GOG Foundation (1) · Gynecologic Oncology Group (1) · Mansoura University (1) · Masonic Cancer Center, University of Minnesota (1) · Mayo Clinic (1) · Novartis Pharmaceuticals (1) · University of Chicago (1) · University of Washington (1)
United States (14) · Canada (1) · Egypt (1) · Singapore (1)
Amar Patel, MD (1) · Amit M Oza (1) · Anil K. Sood, MD (1) · Anil Sood (1) · Barbara Goff (1) · Bradley J Monk (1) · Bradley J. Monk, MD (1) · Dan Veljovich, MD (1) · Don Dizon (1) · Evanthia Galanis, MD (1) · Leona A. Holmberg, MD, PhD (1) · Melissa A. Geller, MD (1) · Michael Gold (1) · Michael Heinrich, MD (1) · Pamela Paley, MD (1)
PMID 19451433, PMID 20837357, PMID 28453702, PMID 30309721, PMID 33485453, PMID 37185961, PMID 37407274
U10CA027469 (3), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM62204 (1), P50CA136393 (1), R01CA136547 (1), R01CA200507 (1), U10CA180821 (1), U10CA180868 (1), UM1CA186644 (1), UM1CA186705 (1)